Daphne Taylor - Mar 3, 2023 Form 4 Insider Report for Aptevo Therapeutics Inc. (APVO)

Role
SVP, CFO
Signature
/s/ SoYoung Kwon, Attorney-in-Fact
Stock symbol
APVO
Transactions as of
Mar 3, 2023
Transactions value $
$0
Form type
4
Date filed
3/7/2023, 03:41 PM
Next filing
Aug 10, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction APVO Common Stock Options Exercise +1.58K +41.22% 5.42K Mar 4, 2023 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction APVO Stock Option (right to buy) Award $0 +11K $0.00 11K Mar 3, 2023 Common Stock 11K $2.15 Direct F2
transaction APVO Restricted Stock Unit Award $0 +11K $0.00 11K Mar 3, 2023 Common Stock 11K Direct F1, F3
transaction APVO Restricted Stock Unit Options Exercise $0 -1.58K -33.33% $0.00 3.17K Mar 4, 2023 Common Stock 1.58K Direct F1, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Restricted Stock Units ("RSUs") convert into common stock, $0.001 par value per share, of the Issuer on a one-for-one basis.
F2 The option vests in three approximately equal annual installments beginning on March 2, 2024.
F3 The RSUs vest in three approximately equal annual installments beginning on March 2, 2024.
F4 On June 7, 2022, the reporting person was granted 4,750 RSUs, vesting in three approximately equal annual installments beginning on March 4, 2023.